{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:34:21Z","timestamp":1791232461733,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":5764,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["li.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Laboratory Investigation"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1038\/labinvest.3700524","type":"journal-article","created":{"date-parts":[[2007,1,29]],"date-time":"2007-01-29T04:44:25Z","timestamp":1170045865000},"page":"365-371","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation"],"prefix":"10.1016","volume":"87","author":[{"given":"Nami","family":"Nakagomi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichi","family":"Hirota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/labinvest.3700524_bib1","series-title":"World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Haematopoietic and Lymphoid tissues","first-page":"293","article-title":"Mastocytosis","author":"Valent","year":"2001"},{"key":"10.1038\/labinvest.3700524_bib2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0145-2126(03)00259-5","article-title":"Response to therapy with interferon alpha-2b and prednisolon in aggressive systemic mastocytosis","volume":"28","author":"Hauswirth","year":"2004","journal-title":"Leuk Res"},{"key":"10.1038\/labinvest.3700524_bib3","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of masatocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"10.1038\/labinvest.3700524_bib4","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/335088a0","article-title":"The protp-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus","volume":"335","author":"Chabot","year":"1988","journal-title":"Nature"},{"key":"10.1038\/labinvest.3700524_bib5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0092-8674(90)90302-U","article-title":"Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor","volume":"63","author":"Zsebo","year":"1990","journal-title":"Cell"},{"key":"10.1038\/labinvest.3700524_bib6","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1242\/dev.116.2.369","article-title":"Requirement of c-kit for development of intestinal pacemaker system","volume":"116","author":"Maeda","year":"1992","journal-title":"Development"},{"key":"10.1038\/labinvest.3700524_bib7","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1172\/JCI116761","article-title":"Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product","volume":"92","author":"Furitsu","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1038\/labinvest.3700524_bib8","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder","volume":"92","author":"Nagata","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/labinvest.3700524_bib9","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1073\/pnas.96.4.1609","article-title":"Activating and dominant inactivatingc-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis","volume":"96","author":"Longley","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/labinvest.3700524_bib10","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1126\/science.279.5350.577","article-title":"Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors","volume":"279","author":"Hirota","year":"1998","journal-title":"Science"},{"key":"10.1038\/labinvest.3700524_bib11","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1046\/j.1523-1747.1998.00414.x","article-title":"Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior","volume":"111","author":"Bittner","year":"1998","journal-title":"J Invest Dermatol"},{"key":"10.1038\/labinvest.3700524_bib12","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"key":"10.1038\/labinvest.3700524_bib13","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0002-9440(10)64946-2","article-title":"KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors","volume":"156","author":"Lux","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1038\/labinvest.3700524_bib14","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH818>3.0.CO;2-E","article-title":"Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours","volume":"193","author":"Hirota","year":"2001","journal-title":"J Pathol"},{"key":"10.1038\/labinvest.3700524_bib15","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1440-1746.2003.02911.x","article-title":"c-kit gene mutation at exon 17 or 13 is very rare in sporadic gastrointestinal stromal tumors","volume":"18","author":"Kinoshita","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1038\/labinvest.3700524_bib16","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","article-title":"The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations","volume":"99","author":"Ma","year":"2002","journal-title":"Blood"},{"key":"10.1038\/labinvest.3700524_bib17","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/sj.onc.1206120","article-title":"Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms","volume":"22","author":"Zermati","year":"2003","journal-title":"Oncogene"},{"key":"10.1038\/labinvest.3700524_bib18","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1038\/labinvest.3700524_bib19","first-page":"4297","article-title":"Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors","volume":"59","author":"Taniguchi","year":"1999","journal-title":"Cancer Res"},{"key":"10.1038\/labinvest.3700524_bib20","first-page":"8118","article-title":"KIT activation is a ubiquitous feature of gastrointestinal stromal tumors","volume":"61","author":"Rubin","year":"2001","journal-title":"Cancer Res"},{"key":"10.1038\/labinvest.3700524_bib21","first-page":"3329","article-title":"Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors","volume":"9","author":"Antonescu","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1038\/labinvest.3700524_bib22","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1053\/j.gastro.2006.01.043","article-title":"Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis","volume":"130","author":"Andersson","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1038\/labinvest.3700524_bib23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.semdp.2006.08.006","article-title":"KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs)","volume":"23","author":"Lasota","year":"2006","journal-title":"Semin Diagn Pathol"},{"key":"10.1038\/labinvest.3700524_bib24","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ijc.20305","article-title":"Different inhibitory effect of imatinib on phosphorylation of mitogen-activated protein kinase and Akt and on proliferation in cells expressing different types of mutant platelet-derived growth factor receptor-alpha","volume":"111","author":"Ohashi","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1038\/labinvest.3700524_bib25","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1038\/sj.onc.1204590","article-title":"STAT3 activation is required for Asp(816) mutant c-Kit induced tumorigenicity","volume":"20","author":"Ning","year":"2001","journal-title":"Oncogene"},{"key":"10.1038\/labinvest.3700524_bib26","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V96.3.925","article-title":"Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor","volume":"96","author":"Heinrich","year":"2000","journal-title":"Blood"},{"key":"10.1038\/labinvest.3700524_bib27","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood-2004-12-4617","article-title":"Activation mutation of human c-KIT resistant to imatinib mesylateare sensitive to the tyrosine kinase inhibitor PKC412","volume":"106","author":"Growney","year":"2005","journal-title":"Blood"},{"key":"10.1038\/labinvest.3700524_bib28","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.CAN-05-2050","article-title":"Dasatinib (BMS-354825), a dualSRC\/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies","volume":"66","author":"Schittenhelm","year":"2006","journal-title":"Cancer Res"},{"key":"10.1038\/labinvest.3700524_bib29","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1182\/blood-2004-06-2189","article-title":"Sensitivity of oncogenic KIT mutants to the kinase inhibitors LN518 and PD180970","volume":"104","author":"Corbin","year":"2004","journal-title":"Blood"},{"key":"10.1038\/labinvest.3700524_bib30","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood-2004-12-4771","article-title":"In vitro in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit","volume":"106","author":"Corbin","year":"2005","journal-title":"Blood"}],"container-title":["Laboratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/3700524.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/3700524","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683722017147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683722017147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/3700524.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T19:42:08Z","timestamp":1758397328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0023683722017147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S0023683722017147"],"URL":"https:\/\/doi.org\/10.1038\/labinvest.3700524","relation":{},"ISSN":["0023-6837"],"issn-type":[{"value":"0023-6837","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation","name":"articletitle","label":"Article Title"},{"value":"Laboratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/labinvest.3700524","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2007 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}